RecruitingPhase 3NCT07734844

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

A Randomized, Double-masked, Active-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Tedromer 5 mg Compared With Intravitreal Aflibercept 2 mg in Participants With Visual Impairment Secondary to Diabetic Macular Edema (DME) - ALTO

Sponsor

Kodiak Sciences Inc

Enrollment

910 participants

Start Date

Aug 3, 2026

Study Type

INTERVENTIONAL

Conditions

Diabetic Macular Edema (DME)

Summary

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aflibercept (2.0 mg) and a drug called Tabirafusp tedromer for people with diabetic macular edema (dme). The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTabirafusp tedromer

Intravitreal injection

DRUGAflibercept (2.0 mg)

Intravitreal injection

Locations(9)

Kodiak Research Center

Glendale, California, United States

Kodiak Research Center

Pasadena, California, United States

Kodiak Research Center

St. Petersburg, Florida, United States

Kodiak Research Center

Hagerstown, Maryland, United States

Kodiak Research Center

Saint Louis Park, Minnesota, United States

Kodiak Research Center

Beaufort, South Carolina, United States

Kodiak Research Center

Charleston, South Carolina, United States

Kodiak Research Center

Ladson, South Carolina, United States

Kodiak Research Center

West Columbia, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07734844

Related Trials

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

NCT07812090

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT0744993670 locations

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT0744992368 locations

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

NCT075200451 location

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

NCT0751507950 locations